Download PDF
Z Gastroenterol 2020; 58(10): 1003-1005
DOI: 10.1055/a-1162-1200
Kommentiertes Referat

Einfluss von ASS auf das Hepatozelluläre Karzinom und die Leber-bedingte Mortalität

Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Alexander Kusnik
  Sektion Hepatologie, II. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg
,
Andreas Teufel
  Sektion Hepatologie, II. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. N Engl J Med 2020; 382:1018–1028



Publication History

Article published online:
09 October 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Venook AP, Papandreou C, Furuse J. et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (Suppl. 04) 5-13
    CrossrefPubMedGoogle Scholar
  • 2 Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171
    CrossrefPubMedGoogle Scholar
  • 3 Barnes B, Kraywinkel K, Nowossadeck E. et al. Bericht zum Krebsgeschehen in Deutschland 2016. 2016; DOI: 10.17886/rkipubl-2016-014.
    CrossrefPubMedGoogle Scholar
  • 4 Schönfeld I, Kraywinkel K. Epidemiologie des hepatozellulären Karzinoms in Deutschland. Onkologe 2018; 24: 653-658
    CrossrefPubMedGoogle Scholar
  • 5 El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127
    CrossrefPubMedGoogle Scholar
  • 6 Kudo M. Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer 2012; 1: 141-143
    CrossrefPubMedGoogle Scholar
  • 7 Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China. Medicine (Baltimore) 2019; 98: e14070
    CrossrefPubMedGoogle Scholar
  • 8 Wang Z, Gu X, Thrift AP. Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. PLoS One 2019; 14: e0214721
    CrossrefPubMedGoogle Scholar
  • 9 Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 2009; 286: 29-37
    CrossrefPubMedGoogle Scholar
  • 10 Simon TG, Ma Y, Ludvigsson JF. et al. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol 2018; 4: 1683-1690
    CrossrefPubMedGoogle Scholar
  • 11 Li J, Hernanda PY, Bramer WM. et al. Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2015; 10: e0127967
    CrossrefPubMedGoogle Scholar
  • 12 Zhang ZJ, Zheng ZJ, Shi R. et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 2347-2353
    CrossrefPubMedGoogle Scholar
  • 13 Donadon V, Balbi M, Mas MD. et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758
    CrossrefPubMedGoogle Scholar
  • 14 Simon TG, Duberg AS, Aleman S. et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med 2020; 382: 1018-1028
    CrossrefPubMedGoogle Scholar
  • 15 Zhang H, Gao C, Fang L. et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78-87
    CrossrefPubMedGoogle Scholar
  • 16 Sitia G, Aiolfi R, Di Lucia P. et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012; 109: E2165-E2172
    CrossrefPubMedGoogle Scholar
  • 17 Liu YX, Feng JY, Sun MM. et al. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta Pharmacol Sin 2019; 40: 122-132
    CrossrefPubMedGoogle Scholar
  • 18 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?. Cell Biosci 2011; 1: 5
    CrossrefPubMedGoogle Scholar
  • 19 Wang T, Fu X, Jin T. et al. Aspirin targets P4HA2 through inhibiting NF-kappaB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine 2019; 45: 168-180
    CrossrefPubMedGoogle Scholar
  • 20 Koh WP, Robien K, Wang R. et al. Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study. Br J Cancer 2011; 105: 1430-1435
    CrossrefPubMedGoogle Scholar
  • 21 Chan HL, Wong VW, Wong GL. et al. Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol 2009; 47: 1830-1836
    CrossrefPubMedGoogle Scholar
  • 22 Carrat F, Fontaine H, Dorival C. et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393: 1453-1464
    CrossrefPubMedGoogle Scholar
  • 23 O’Rourke JM, Sagar VM, Shah T. et al. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24: 4436-4447
    CrossrefPubMedGoogle Scholar
  • 24 Kansagara D, Papak J, Pasha AS. et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med 2014; 161: 261-269
    CrossrefPubMedGoogle Scholar
  • 25 Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010; 31: 71-82
    CrossrefPubMedGoogle Scholar
  • 26 Smela ME, Hamm ML, Henderson PT. et al. The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2002; 99: 6655-6660
    CrossrefPubMedGoogle Scholar
  • 27 Bravi F, Bosetti C, Tavani A. et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1413-1421 e1411
    CrossrefPubMedGoogle Scholar
  • 28 McNeil JJ, Wolfe R, Woods RL. et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018; 379: 1509-1518
    CrossrefPubMedGoogle Scholar
  • 29 Group ASC, Bowman L, Mafham M. et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379: 1529-1539
    CrossrefPubMedGoogle Scholar
  • 30 Saito Y, Okada S, Ogawa H. et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation 2017; 135: 659-670
    CrossrefPubMedGoogle Scholar
  • 31 Alexander M, Loomis AK, van der Lei J. et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med 2019; 17: 95
    CrossrefPubMedGoogle Scholar
  • 32 Kim G, Jang SY, Nam CM. et al. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J Hepatol 2018; 68: 476-484
    CrossrefPubMedGoogle Scholar
  • 33 Kennedy OJ, Roderick P, Buchanan R. et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017; 7: e013739
    CrossrefPubMedGoogle Scholar